The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer - A retrospective analysis

被引:111
作者
Toh, CK
Wong, EH
Lim, WT
Leong, SS
Fong, KW
Wee, J
Tan, EH
机构
[1] Natl Canc Ctr, Dept Med Oncol, Singapore 169610, Singapore
[2] Natl Canc Ctr, Dept Therapeut Radiol, Singapore 169610, Singapore
[3] Natl Canc Ctr, Div Clin Trials & Epidemiol Sci, Singapore 169610, Singapore
关键词
chemotherapy; non-small cell lung cancer; smoking; survival;
D O I
10.1378/chest.126.6.1750
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: There are fundamental differences in characteristics between smokers and nonsmokers with non-small cell lung cancer (NSCLC). We aim to study the impact of smoking status on the behavior of the disease, and to identify differences in outcome between the two groups. Design: A retrospective analysis was done of patients with NSCLC seen during the period from January 1999 to August 2002. Clinical characteristics, survival outcome, and response to treatment were reviewed and compared between the smokers and nonsmokers. Setting: Department of Medical Oncology, National Cancer Center. Results: Of 317 patients analyzed, 117 patients (36.3%) were nonsmokers. Among the nonsmokers, 74.5% had adenocarcinoma and 73.9% were women. The smokers had poorer performance status, reported more weight loss, and had a higher mean age at diagnosis of almost 8 years than nonsmokers. One hundred eighty-seven patients (59%) had died as of December 31, 2002. The nonsmokers had a longer median survival, although this was not statistically significant. There were no statistically significant differences in survival and response to chemotherapy between the two groups after adjusting for known prognostic factors. Conclusions: Despite the known differences in mutational spectra and clinical characteristics between smokers and nonsmokers with NSCLC, no differences in terms of response to chemotherapy and survival outcome were observed. This could imply that this disease is equally aggressive in these two groups. More research is needed to further delineate and characterize the differences between these two etiologically different forms of NSCLC.
引用
收藏
页码:1750 / 1756
页数:7
相关论文
共 43 条
[1]  
Ahrendt SA, 2000, CANCER RES, V60, P3155
[2]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[3]  
[Anonymous], WHO PUBL
[4]  
*CDCP, 2002, MMWR-MORBID MORTAL W, V51, P642
[5]   Risk factors associated with lung cancer in Hong Kong [J].
Chan-Yeung, M ;
Koo, LC ;
Ho, JCM ;
Tsang, KWT ;
Chau, WS ;
Chiu, SW ;
Ip, MSM ;
Lam, WK .
LUNG CANCER, 2003, 40 (02) :131-140
[6]   The increasing incidence of lung adenocarcinoma: Reality or artefact? A review of the epidemiology of lung adenocarcinoma [J].
Charloux, A ;
Quoix, E ;
Wolkove, N ;
Small, D ;
Pauli, G ;
Kreisman, H .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (01) :14-23
[7]  
CHEN CJ, 1990, ANTICANCER RES, V10, P971
[8]  
CHIA KS, 2000, SINGAPORE CANC REGIS, P12
[9]   FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].
Cohen, MH ;
Williams, GA ;
Sridhara, R ;
Chen, G ;
Pazdur, R .
ONCOLOGIST, 2003, 8 (04) :303-306
[10]   A STUDY OF THE AETIOLOGY OF CARCINOMA OF THE LUNG [J].
DOLL, R ;
HILL, AB .
BMJ-BRITISH MEDICAL JOURNAL, 1952, 2 (4797) :1271-1286